Pharma's Almanac TV
PA TV
Follow the Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
FDA
466 Articles Available
1
20
Can't find what you're looking for? Try our
advanced search
.
FDA Approves First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer
PR-M11-20-028
FDA Authorization
Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19
PR-M11-20-022
Fast Track
Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer
PR-M11-20-012
Decentralized Trials
Protecting Clinical Research and Patients Through Decentralized Trial Strategies
PAP-Q3-20-CL-025
Oral COVID-19 Vaccine
Vaxart Announces FDA Clearance of IND Application for Oral COVID-19 Vaccine
PR-M09-20-NI-19
FDA Approval
FDA Approves First-of-its-Kind Automated Insulin Delivery and Monitoring System for Use in Young Pediatric Patients
PR-M09-20-NI-04
COVID-19
Gilead’s Remdesivir Receives FDA Emergency Use Authorization for the Treatment of Patients With Moderate COVID-19
PR-M08-20-NI-48
FDA Approval
Cassiopea Receives FDA Approval for Acne Drug
PR-M08-20-NI-44
FDA
FDA Accepts Application for Xolair Prefilled Syringe for Self-Administration Across All Indications
PR-M08-20-NI-32
Diagnostic Testing
FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect COVID-19 Test
PR-M08-20-NI-27
Liquid Biopsy
FDA Approves First Liquid Biopsy Next-Generation Sequencing Companion Diagnostic Test
PR-M08-20-NI-17
FDA Approval
FDA Approves GSK’s BLENREP for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
PR-M08-20-NI-11
COVID-19 Treatment
Common FDA-Approved Drug May Effectively Neutralize Virus That Causes COVID-19
PR-M07-20-NI-32
COVID-19 Testing
FDA Issues First Emergency Authorization for Sample Pooling in Diagnostic Testing
PR-M07-20-NI-29
FDA
FDA Prepares for Resumption of Domestic Inspections with New Risk Assessment System
PR-M07-20-NI-016
FDA
FDA Takes Action to Help Facilitate Timely Development of Safe, Effective COVID-19 Vaccines
PR-M06-20-NI-041
COVID-19
Regulating Clinical Trials in Pandemic Times
PAP-Q2-20-NI-005
Predictive Analytics
CLEW Receives FDA Emergency Use Authorization for Its Predictive Analytics Platform in Support of COVID-19 Patients
PR-M06-20-NI-038
FDA Approval
FDA Approves First-Of-Its-Kind Percep PC Neurostimulator with BrainSense Technology
PR-M06-20-NI-037
COVID-19 Testing
The FDA Confirms Certain COVID-19 Serology and Antibody Tests Should Not Be Used
PR-M06-20-NI-035
Clinical Trials
FDA Announces First of Its Kind Pilot Program to Communicate Patient Reported Outcomes from Cancer Clinical Trials
PR-M06-20-NI-032
FDA Approval
FDA Permits Marketing of First Game-Based Digital Therapeutic to Improve Attention Function in Children with ADHD
PR-M06-20-NI-021
FDA Alert
FDA Alerts Patients of Amneal and Impax Laboratories Epinephrine Auto-Injector Device Malfunctions
PR-M06-20-NI-015
FDA Accepts Shionogi’s Supplemental New Drug Application for the Treatment of Ventilator-Associated Bacterial Pneumonia
PR-M06-20-NI-013
1
20
»
